Navigation Links
ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company
Date:7/28/2014

IRVINE, Calif., July 28, 2014 /PRNewswire/ -- ALPHAEON Corporation®, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired Physician Recommended Nutriceuticals (PRN)®, a leading developer of specialty omega-3s, and related products for dry eye and macular degeneration, based in Plymouth Meeting, PA, in a transaction worth up to $55M.

"ALPHAEON's acquisition of PRN brings together world renowned ophthalmologists and a premier physician recommended line of nutriceutical products that benefit patients," said CEO Robert E. Grant. "Over the past 5 years, PRN has established a strong leadership position in the rapidly growing field of evidence-based physician recommended and dispensed nutriceuticals, achieving consistently high double-digit growth over several years. We are very pleased to partner with such a quality organization and leadership team and look forward to maintaining their stand-alone operation just outside of Philadelphia, Pennsylvania. This acquisition brings significant customer synergies to both organizations and is ideally aligned to ALPHAEON's mission to provide best-in-class wellness related products to patients."

PRN's dry eye patent pending formula has the highest bioavailable concentration per serving of purified omega-3 fatty acids and the optimal ratio of 3:1 EPA/DHA. Dry Eye Omega Benefits® has been clinically proven to address the inflammation leading to dry eye and improve the recovery time from refractive and cataract surgery. In a dry eye clinical study, 82% of patients who consumed PRN's re-esterified triglyceride (rTG) omega-3 product for an eight-week period had a positive change in the composition of their meibum, a potential root cause of dry-eye syndrome.

PRN CEO Ken Krieg stated, "ALPHAEON's uniquely customer-centric business approach enables physicians to provide world-class products, addressing patient lifestyle and clinical needs. PRN products are created to offer condition-specific solutions while promoting overall patient wellness and are backed by human clinical efficacy studies. This acquisition is well timed to expand the reach of PRN's evidence-based nutriceuticals through ALPHAEON's platform of physician selected services and industry leading marketing campaigns."

Last year, more than 1,200 ophthalmologists in North America recommended PRN's dry eye products and over 100,000 patients have ordered and used PRN products. ALPHAEON will begin offering the omega-3 products to its approximately 1,000 physician customers, participating in ALPHAEON's customer affinity program, commencing on August 1, 2014.

About ALPHAEON Corporation

ALPHAEON Corporation is a lifestyle healthcare company committed to partnering with board-certified physicians to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. Ensuring access to leading advancements in lifestyle healthcare, the company fosters deep relationships with leading specialty physicians so patients look their best, feel their best and know they are receiving the best in lifestyle healthcare. For more information, please visit www.alphaeon.com

About Strathspey Crown

Strathspey Crown is a growth equity firm specializing in lifestyle healthcare. Strathspey Crown uniquely partners with board certified physician specialists to bring to market highly innovative technologies and services in the self-pay sector. The firm is founded in partnership with physician investors across three key medical specialties: plastic surgery, ophthalmology and dermatology. For more information visit www.strathspeycrown.com.

About Physician Recommended Nutriceuticals

PRN is a leading developer of condition-specific omega-3 products and nutritional supplements. Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and offer exceptional quality and purity. Acknowledged on the Inc. 500|5000 list of fastest growing privately held companies for the third consecutive year, PRN has demonstrated three-year revenue growth of 375%.

PRESS CONTACT:

Jenna Mons, Vice President of Marketing and Communications
Tel: 949-284-4523
Email: press@alphaeon.com  

David Krieg, Director of Communications
Tel: 610-276-1954
Email: dkrieg@prnomegahealth.com   

ALPHAEON® is a registered trademark of ALPHAEON
PRN® is a registered trademark of Physician Recommended Nutriceuticals  
Omega Benefits® is a registered trademark of Physician Recommended Nutriceuticals 

Logo - http://photos.prnewswire.com/prnh/20140728/130500


'/>"/>
SOURCE ALPHAEON Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration
2. ACON Investments Acquires Injured Workers Pharmacy
3. Chiltern acquires Ockham and the companies merge operations
4. Cantel Medical Acquires Sterilator Company, Inc.
5. Data Sciences International acquires Buxco Research Company to expand preclinical research solutions offering
6. BD Acquires Alverix, Inc.
7. Numotion Acquires Specialty Wheelchairs, LLC
8. Aratana Therapeutics Acquires Okapi Sciences NV
9. 180 Medical Acquires Symbius Medical
10. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
11. PTS, Inc. Acquires A1CNow and Expands Product Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):